Payment overview · 2025
General Payments
$377.82
3 reported records · 3 companies
Healthcare provider profile · identity verified
Melchor Madarang, MD
Allopathic & Osteopathic Physicians|Family Medicine · OXFORD, FL · NPI 1013975366
Verified facts
What the public records show
CMS Open Payments records show Melchor Madarang, MD received $377.82 in general payments during 2025 across 3 reported records.
Dexcom, Inc. accounted for 34.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $130.81 | 34.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.01 | 32.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $123.00 | 32.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $377.82 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $130.81 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $130.81 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $124.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 701 | 232 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 476 | 160 |
| Lisinopril | Lisinopril | 436 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 434 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 389 | 127 |
| Metformin Hcl | Metformin Hcl | 302 | 102 |
| Losartan Potassium | Losartan Potassium | 297 | 98 |
| Simvastatin | Simvastatin | 255 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 225 | 74 |
| Omeprazole | Omeprazole | 212 | 80 |
| Ezetimibe | Ezetimibe | 207 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 204 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 185 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 57 |
| Eliquis | Apixaban | 173 | 53 |
| Gabapentin | Gabapentin | 165 | 71 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 144 | 115 |
| Trazodone Hcl | Trazodone Hcl | 120 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 116 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 37 |
| Allopurinol | Allopurinol | 105 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 49 |
| Methylprednisolone | Methylprednisolone | 101 | 93 |
| Finasteride | Finasteride | 98 | 29 |
| Carvedilol | Carvedilol | 97 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 36 |
| Furosemide | Furosemide | 94 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 24 |
| Sertraline Hcl | Sertraline Hcl | 84 | 30 |
| Metformin Hcl Er | Metformin Hcl | 82 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 26 |
| Montelukast Sodium | Montelukast Sodium | 77 | 23 |
| Atenolol | Atenolol | 72 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 22 |
| Potassium Chloride | Potassium Chloride | 69 | 24 |
| Azithromycin | Azithromycin | 67 | 60 |
| Alprazolam | Alprazolam | 58 | 38 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 58 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 34 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 20 |
| Donepezil Hcl | Donepezil Hcl | 52 | 15 |
| Propranolol Hcl | Propranolol Hcl | 51 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 29 |
| Valsartan | Valsartan | 48 | 17 |
| Januvia | Sitagliptin Phosphate | 47 | 12 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 46 | 14 |
| Fluconazole | Fluconazole | 46 | 36 |
| Famotidine | Famotidine | 44 | 18 |
| Baclofen | Baclofen | 42 | 13 |
| Pregabalin | Pregabalin | 42 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 12 |
| Tramadol Hcl | Tramadol Hcl | 41 | 29 |
| Glimepiride | Glimepiride | 40 | 14 |
| Farxiga | Dapagliflozin Propanediol | 39 | 11 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Xarelto | Rivaroxaban | 35 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 13 |
| Chlorthalidone | Chlorthalidone | 32 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 12 |
| Valacyclovir | Valacyclovir Hcl | 32 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 28 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | 11 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 21 |
| Sildenafil Citrate | Sildenafil Citrate | 24 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Prednisone | Prednisone | 22 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 18 |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 13 |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Nexletol | Bempedoic Acid | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Strensiq | Asfotase Alfa | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $377.82 · 3 records | Dexcom, Inc. | DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, VOQUEZNA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error